Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission.
In this double-blind, placebo-controlled study, we examined the effects of subanaesthetic doses of ketamine (an NMDA glutamate receptor antagonist) and thiopental (a GABA-A receptor agonist) on the event-related potential (ERP) correlates of deviant stimulus processing in 24 healthy adults. Participants completed three separate pharmacological challenge sessions (ketamine, thiopental, saline) in a counterbalanced order. EEG data were recorded both before and during each challenge while participants performed a visual 'oddball' task consisting of infrequent 'target' and 'novel' stimuli intermixed with frequent 'standard' stimuli. We examined drug effects on the amplitude and latency of the P300 (P3) component of the ERP elicited by target (P3b) and novel stimuli (P3a), as well as the N200 (N2) component elicited by both target and novel stimuli, and the N100 (N1) elicited by standard stimuli. Relative to placebo, both drugs reduced the amplitude of parietal P3b. While both drugs reduced parietal P3a and Novelty N2, ketamine also shortened P3a latency, reduced Novelty N2 amplitude more than thiopental, and increased frontal P3a amplitude relative to placebo. Overall, the data suggest that both the GABA-A and NMDA receptor systems modulate P3b and P3a. NMDA antagonism appears to lead to more varied effects on the neural correlates of novelty processing.
Watson
Todd D
TD
NIAAA Center for the Translational Neuroscience of Alcoholism and Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. toddw@lclark.edu
Petrakis
Ismene L
IL
Edgecombe
Javon
J
Perrino
Albert
A
Krystal
John H
JH
Mathalon
Daniel H
DH
D000328:Adult; D000704:Analysis of Variance; D002540:Cerebral Cortex / Q000187:drug effects* / Q000502:physiology; D004311:Double-Blind Method; D004569:Electroencephalography / Q000379:methods; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology*; D005260:Female; D018757:GABA Modulators / Q000494:pharmacology*; D006801:Humans; D007649:Ketamine / Q000494:pharmacology; D008297:Male; D010147:Pain Measurement; D010364:Pattern Recognition, Visual / Q000502:physiology; D010775:Photic Stimulation / Q000379:methods; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D018080:Receptors, GABA-B / Q000378:metabolism*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013223:Statistics as Topic; D013874:Thiopental / Q000494:pharmacology*; D055815:Young Adult
D018757:GABA Modulators; D018080:Receptors, GABA-B; D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine; D013874:Thiopental
Cereb Cortex. 2005 Jun;15(6):749-59
15537676
Electroencephalogr Clin Neurophysiol. 1991 Feb;78(2):142-9
1704837
Psychophysiology. 2002 Mar;39(2):147-57
12212663
Cogn Affect Behav Neurosci. 2003 Mar;3(1):17-26
12822595
Psychol Bull. 2005 Jul;131(4):510-32
16060800
Int J Psychophysiol. 2006 May;60(2):172-85
16510201
Nature. 1996 Sep 19;383(6597):256-9
8805701
Schizophr Bull. 2007 Jul;33(4):848-52
17567628
Anesth Analg. 1991 Nov;73(5):612-8
1952143
Clin EEG Neurosci. 2006 Oct;37(4):309-14
17073169
Psychophysiology. 2003 Nov;40(6):914-23
14986844
J Cogn Neurosci. 2002 May 15;14(4):593-602
12126500
Neuroreport. 2005 Nov 28;16(17):1933-7
16272882
Neuropsychobiology. 1999;40(2):86-94
10474063
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
8122957
Crit Rev Neurobiol. 2000;14(3-4):199-224
12645958
Psychopharmacology (Berl). 2007 Jul;192(4):511-9
17318501
Electroencephalogr Clin Neurophysiol. 1984 Feb;59(1):9-20
6198170
Electroencephalogr Clin Neurophysiol. 1975 Aug;39(2):131-43
50210
J Clin Neurophysiol. 1992 Oct;9(4):456-79
1464675
Biol Psychol. 2003 Oct;64(1-2):119-41
14602358
Psychiatry Clin Neurosci. 1999 Apr;53(2):185-7
10459684
Neuropsychopharmacology. 2000 Mar;22(3):293-302
10693157
Psychopharmacology (Berl). 2005 Apr;179(1):303-9
15309376
Brain Res Cogn Brain Res. 2005 Feb;22(2):221-31
15653295
Neuropsychopharmacology. 2004 Jun;29(6):1203-14
15100698
Int J Psychophysiol. 2006 Jan;59(1):8-14
16253363
Clin Neurophysiol. 2006 Aug;117(8):1638-40
16798078
Electroencephalogr Clin Neurophysiol. 1998 Feb;106(2):156-64
9741777
Clin Neurophysiol. 2007 Oct;118(10):2128-48
17573239
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):1013-21
14499319
Brain Cogn. 2004 Oct;56(1):5-13
15380870
Brain Cogn. 2004 Nov;56(2):165-76
15518933
Behav Brain Res. 1990 Jul 9;39(2):187-95
2167694
Brain Topogr. 2003 Spring;15(3):141-52
12705810
Clin Neurophysiol. 2004 Apr;115(4):732-44
15003751
Clin Neurophysiol. 2007 May;118(5):1069-77
17368096
Acta Psychol (Amst). 1999 Apr;101(2-3):267-91
10344188
Electroencephalogr Clin Neurophysiol. 1983 Apr;55(4):468-84
6187540
Arch Gen Psychiatry. 2005 Sep;62(9):985-94
16143730
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):993-9
14499316
Physiol Behav. 2002 Dec;77(4-5):477-82
12526986
Electroencephalogr Clin Neurophysiol. 1975 Apr;38(4):387-401
46819
Biol Psychol. 1997 Aug 22;46(2):113-24
9288409